CLINICAL TRIALS PROFILE FOR TOFACITINIB
✉ Email this page to a colleague
505(b)(2) Clinical Trials for TOFACITINIB
| Trial Type | Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|---|
| New Indication | NCT04925973 ↗ | Tofacitinib for Hospitalized Acute Severe Ulcerative Colitis Management | Recruiting | McGill University | Phase 2 | 2021-06-01 | The TRIUMPH study was designed to build on the existing literature by studying the efficacy of tofacitinib in hospitalized patients with acute severe ulcerative colitis. This trial will provide evidence for a possible new indication for the use of tofacitinib. |
| New Indication | NCT04925973 ↗ | Tofacitinib for Hospitalized Acute Severe Ulcerative Colitis Management | Recruiting | University of Alberta | Phase 2 | 2021-06-01 | The TRIUMPH study was designed to build on the existing literature by studying the efficacy of tofacitinib in hospitalized patients with acute severe ulcerative colitis. This trial will provide evidence for a possible new indication for the use of tofacitinib. |
| New Indication | NCT04925973 ↗ | Tofacitinib for Hospitalized Acute Severe Ulcerative Colitis Management | Recruiting | University of British Columbia | Phase 2 | 2021-06-01 | The TRIUMPH study was designed to build on the existing literature by studying the efficacy of tofacitinib in hospitalized patients with acute severe ulcerative colitis. This trial will provide evidence for a possible new indication for the use of tofacitinib. |
| New Indication | NCT04925973 ↗ | Tofacitinib for Hospitalized Acute Severe Ulcerative Colitis Management | Recruiting | University of Manitoba | Phase 2 | 2021-06-01 | The TRIUMPH study was designed to build on the existing literature by studying the efficacy of tofacitinib in hospitalized patients with acute severe ulcerative colitis. This trial will provide evidence for a possible new indication for the use of tofacitinib. |
| New Indication | NCT04925973 ↗ | Tofacitinib for Hospitalized Acute Severe Ulcerative Colitis Management | Recruiting | McMaster University | Phase 2 | 2021-06-01 | The TRIUMPH study was designed to build on the existing literature by studying the efficacy of tofacitinib in hospitalized patients with acute severe ulcerative colitis. This trial will provide evidence for a possible new indication for the use of tofacitinib. |
| >Trial Type | >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
All Clinical Trials for TOFACITINIB
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00413699 ↗ | Long-Term Effectiveness And Safety Of CP-690,550 For The Treatment Of Rheumatoid Arthritis | Completed | Pfizer | Phase 3 | 2007-02-05 | The purpose of this study is to determine the long-term effectiveness and safety of CP-690,550 for the treatment of rheumatoid arthritis. Subjects are eligible for this study only after participating in another "qualifying" study of CP-690,550 A sub-study will be conducted within the A3921024 study, this study will evaluate the immune response to pneumococcal and influenza vaccines in patients receiving CP-690,550 |
| NCT01164579 ↗ | Effects of Tofacitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA) | Completed | Pfizer | Phase 2 | 2010-10-01 | Evaluation of efficacy and safety of tofacitinib (CP-690,550) for the treatment of early rheumatoid arthritis in adult patients with moderate to severe disease who are methotrexate naïve. The efficacy will be evaluated by exploring the effects on joint structure assessed by magnetic resonance imaging, x-rays and by standard clinical assessment. |
| NCT01375127 ↗ | Collection of Follow-up Data From CP-690,550-treated Kidney Transplant Recipients | Completed | Pfizer | 2011-08-01 | This is an observational study designed to collect follow-up clinical date on subjects who were treated with tofacitinib in 2 completed Phase 2 studies who either discontinued treatment prematurely or did not elect to enroll in long-term extension studies. | |
| NCT01458951 ↗ | A Study To Evaluate Both The Efficacy and Safety Profile of CP-690,550 In Patients With Moderately to Severely Active Ulcerative Colitis | Completed | Pfizer | Phase 3 | 2012-06-01 | This study is designed to evaluate the efficacy and safety of tofacitinib (CP-690,550) in patients with moderate to severe ulcerative colitis who have failed or be intolerant to one of following treatments for ulcerative colitis: oral steroids, azathiopurine/6-mercaptopurine, or anti-TNF-alpha therapy. |
| NCT01465763 ↗ | A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative Colitis | Completed | Pfizer | Phase 3 | 2012-04-01 | This study is designed to evaluate the efficacy and safety of tofacitinib (CP-690,550) in patients with moderate to severe ulcerative colitis who have failed or be intolerant to one of following treatments for ulcerative colitis: oral steroids, azathiopurine/6-mercaptopurine, or anti-TNF-alpha therapy. |
| NCT01484561 ↗ | A Study To Evaluate The Effect Of CP-690,550 On Measures Of Kidney Function In Patients With Active Rheumatoid Arthritis | Completed | Pfizer | Phase 1 | 2012-04-01 | The purpose of study is to explore the effect of CP-690,550 (Tofacitinib) on measures of kidney function in patients with active rheumatoid arthritis (RA). |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for TOFACITINIB
Condition Name
Clinical Trial Locations for TOFACITINIB
Trials by Country
Clinical Trial Progress for TOFACITINIB
Clinical Trial Phase
Clinical Trial Sponsors for TOFACITINIB
Sponsor Name
